as of 08-14-2026 1:17pm EST
CytoSorbents Corp is a leader in blood purification for the treatment of life-threatening conditions in the intensive care unit and cardiac surgery. CytoSorbent's proprietary blood purification technologies are based on biocompatible, high-porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbent's technologies are used in several broad applications. Specifically, two important applications are: the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and the removal of inflammatory agents and toxins in common critical illnesses that can cause massive inflammation, organ failure, and patient death. Geographically, in the USA, Germany, and Others.
| Founded: | 1997 | Country: | United States |
| Employees: | N/A | City: | PRINCETON |
| Market Cap: | 23.9M | IPO Year: | 2008 |
| Target Price: | $5.38 | AVG Volume (30 days): | 58.7K |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.15 | EPS Growth: | 65.79 |
| 52 Week Low/High: | $0.35 - $1.19 | Next Earning Date: | 05-01-2026 |
| Revenue: | $22,503,908 | Revenue Growth: | 48.53% |
| Revenue Growth (this year): | 10.34% | Revenue Growth (next year): | 22.41% |
| P/E Ratio: | -2.42 | Index: | N/A |
| Free Cash Flow: | -12541000.0 | FCF Growth: | N/A |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Chief Financial Officer
Avg Cost/Share
$0.44
Shares
100,000
Total Value
$44,000.00
Owned After
638,113
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$0.43
Shares
10,333
Total Value
$4,443.19
Owned After
1,744,432
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$0.40
Shares
251,136
Total Value
$100,454.40
Owned After
1,744,432
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| MARIANI PETER J | CTSO | Chief Financial Officer | Jun 15, 2026 | Buy | $0.44 | 100,000 | $44,000.00 | 638,113 | |
| Chan Phillip P. | CTSO | Chief Executive Officer | Jun 15, 2026 | Buy | $0.43 | 10,333 | $4,443.19 | 1,744,432 | |
| Chan Phillip P. | CTSO | Chief Executive Officer | Jun 12, 2026 | Buy | $0.40 | 251,136 | $100,454.40 | 1,744,432 |
SEC 8-K filings with transcript text
Aug 6, 2026 · 99% conf.
1D
+5.37%
$0.42
Act: -9.68%
5D
+10.16%
$0.44
20D
+12.53%
$0.45
2 tm2622246d1_ex99-1.htm
Exhibit 99.1
CytoSorbents Reports Second Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update
Highlighting Four Independent Drivers of Shareholder Value
August 6, 2026 — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today reported financial results for the second quarter ended June 30, 2026, recent business highlights, and provides a regulatory update.
Second Quarter 2026 Financial Results
·Revenue was $9.6 million, unchanged from a year ago.
·Gross margin improved to 73% in the quarter, up sequentially from 69% in Q1 2026 and from 71% a year ago.
·Operating loss improved by 27% to $2.6 million versus $3.6 million in Q2 2025.
·Net loss was $4.4 million or $0.07 per share, compared to net income of $1.9 million or $0.03 per share in Q2 2025, due primarily to the non-cash impact of changes in foreign currency translations year over year.
·Adjusted net loss, which excludes the impact of non-cash changes in foreign currency translations and non-cash stock compensation, improved by 22% to $2.8 million or $0.05 per share, compared to an adjusted net loss of $3.7 million or $0.06 per share in Q2 2025.
·Adjusted EBITDA loss, which also excludes the impact of non-cash changes in foreign currency translations and non-cash stock compensation improved by 38% to $1.6 million compared to a loss of $2.6 million in Q2 2025.
·Total cash, cash equivalents, and restricted cash was approximately $5.9 million on June 30, 2026, compared to $6.3 million at March 31, 2026.
·Total cash burn in the second quarter was reduced to $0.4 million, inclusive of approximately $0.2 million in restructuring-related payments.
“Second quarter revenue performance was led by strong growth in our distributor and strategic partner territories, as well as direct sales outside of Germany, but offset by a decline in sales in Germany attributed to a smaller, but more focused sales force. We are encouraged by the improved productivity and sales execution of this team and expect to add three to five new sales representatives through early 2027 to restore full country coverage,” stated Dr. Phillip Chan, Chief Executive Officer of CytoSorbents. “We are also pleased with the continued improvements in our operating execution in the quarter, including an increase in gross margins to 73%, a 27% reduction in operating loss, a 38% improvement in adjusted EBITDA loss, and importantly, a reduction in operating cash burn to $200,000 excluding restructuring payments. These gains reflect disciplined execution across our organization, including manufacturing optimization, improved working capital management, commercial execution, and tighter cost controls. As a result, we believe we remain on track toward our objective of achieving operating cash flow breakeven in the second half of this year.
Over the past couple of years, our priorities have been clear. We have needed to strengthen the financial foundation of the Company, improve commercial and operating execution, advance our regulatory programs, and position the business for sustainable long-term growth. During the second quarter, we continued making meaningful progress against each of these objectives. While we are not yet where we want to be, we believe CytoSorbents today is better positioned for success than it was a year ago.
Four Independent Value Drivers
Looking ahead, we believe CytoSorbents has strong value creation opportunities. We believe we have four independent value drivers over the next six to eighteen months and that each has the potential to strengthen the business and create meaningful long-term shareholder value by reducing risk, expanding profitability, opening new markets, and unlocking strategic value.
First Value Driver: Achieving Operating Cash Flow Breakeven
Our first value driver is reducing financial risk by achieving sustainable operating cash flow breakeven.
Over the past year, we have focused relentlessly on improving the economics of our business. Product gross margin improved to 73% during the second quarter through manufacturing optimization, improved sourcing, and production efficiencies. We also lowered our cash burn through improved commercial execution, collections, and working capital management while continuing to streamline our organization. Since September 2025, we have reduced our workforce by approximately 23%, creating a leaner and more focused company.
As a result, operating cash burn declined to approximately $200,000 during the quarter, excluding restructuring charges, representing another meaningful step toward operating cash flow breakeven.
We believe this milestone is important because it fundamentally changes the Company's financial profile. Every dollar of operating cash burn eliminated reduces future financing needs, strengthen
May 13, 2026 · 100% conf.
1D
-2.72%
$0.56
Act: -5.05%
5D
-10.96%
$0.51
Act: -17.63%
20D
-4.48%
$0.55
Act: -31.98%
SEC.gov | Request Rate Threshold Exceeded
U.S. Securities and Exchange Commission
You’ve Exceeded the SEC’s Traffic Limit
Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.
Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.
The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.
For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.
For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.
Reference ID: 0.e618d017.1784725702.7cfb61b
More Information
Internet Security Policy
By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.
Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).
To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.
If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.
Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.
Note: We do not offer technical support for developing or debugging scripted downloading processes.
Mar 25, 2026
SEC.gov | Request Rate Threshold Exceeded
U.S. Securities and Exchange Commission
You’ve Exceeded the SEC’s Traffic Limit
Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.
Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.
The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.
For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.
For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.
Reference ID: 0.e618d017.1784725704.7cfcfbf
More Information
Internet Security Policy
By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.
Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).
To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.
If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.
Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.
Note: We do not offer technical support for developing or debugging scripted downloading processes.
See how CTSO stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "CTSO Cytosorbents Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.